Analyst Ratings For AVITA Medical
Portfolio Pulse from Benzinga Insights
AVITA Medical (NASDAQ:RCEL) has been analyzed by 4 analysts in the last three months, showing a shift towards a more cautious stance with 3 somewhat bullish and 1 indifferent rating recently. The average 12-month price target has been adjusted to $19.00, down 9.52% from previous estimates, reflecting a negative sentiment shift. AVITA's RECELL system, a burn treatment device, is a key product, with the company focusing on the US market despite having approvals in other regions. Financially, AVITA has shown significant revenue growth but operates at a net loss, with a strong ROE and ROA compared to industry averages.
May 14, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AVITA Medical's analyst ratings have shown a cautious but somewhat bullish outlook, with a recent decrease in the average price target. The company's focus on the US market for its RECELL system and its financial performance indicators suggest a mixed short-term impact.
The mixed analyst ratings and the recent decrease in the average price target suggest uncertainty about AVITA Medical's short-term stock performance. However, the company's significant revenue growth and strategic focus on the US market for its RECELL system, alongside strong ROE and ROA, indicate underlying strengths that could mitigate negative sentiment. The cautious optimism among analysts, combined with the company's financial performance and strategic focus, suggests a neutral short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100